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Löfgren’s syndrome presents as acute sarcoid arthritis, with a triad of hilar 
adenopathy, acute polyarthritis and erythema nodosum. Löfgren’s syndrome is 
self-limited, erythema nodosum, hilar adenopathy and acute polyarthritis usu-
ally resolve within a few weeks to months, however polyarthritis can last for up to 
2 years. Treatment involves symptomatic control with NSAIDs/colchicine or oral 
glucocorticoids until symptoms resolve, if disease is resistant to these therapies, 
hydroxychloroquine, methotrexate or infliximab can be used. Löfgren’s syndrome is 
a rare presentation of sarcoidosis occurring in only about 5–10% of sarcoid patients. 
It is, however, important to recognize as it is the most common form of acute sar-
coid arthritis and prompt treatment can prevent unnecessary prolonged discomfort 
for patients.
Keywords: Löfgren’s Syndrome, Sarcoidosis, Polyarthritis, Hilar adenopathy, 
Erythema nodosum
1. Introduction
Löfgren’s syndrome is an acute manifestation of sarcoidosis. Sarcoidosis is a 
disease characterized by noncaseating granulomas throughout multiple body 
systems, most commonly involving the lungs (> 90% cases), often manifesting as 
hilar adenopathy. A small subset of patients (~10%) will develop joints symptoms, 
which can manifest as either acute or chronic arthritis. Löfgren’s syndrome is the 
most common presentation of acute sarcoid arthritis, occurring in about 5–10% of 
sarcoid cases, presenting as classical triad of acute polyarthritis, erythema nodosum 
and hilar adenopathy.
2. Epidemiology
Sarcoidosis is a disease with prevalence of about 10 to 20 per 100,000 people, 
it affects a wide variety of patients, but there are certain predilections and pat-
terns for higher disease activity. Geographic area, ethnicity, gender and age seem 
to play important roles in incidence and presentation of disease [1, 2]. Various 
geographic locations have been studied, and there seems to be clustering of sarcoid-
osis incidence around certain geographic areas, with northern countries (such as 
Scandinavia) having much higher incidence than other areas [3]. Ethnicity also has 
a distinct pattern, with African Americans, Scandinavians, Afro Caribbeans, Irish, 
Puerto Rican and North Africans having highest incidence, though this seems to be 
affected by geographical location as well [3, 4]. There are also differences in disease 
presentation between different ethnicities; African Americans seem to have more 
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severe disease presentation than Caucasians [2]. Lowest incidence occurs in Spain 
and Japan [3, 4]. Women are overall more affected by sarcoidosis than men, though 
interestingly, the age of diagnosis is almost 10 years later in women than men in 
many populations [3, 4]. There also seem to be difference in disease presentation 
between women and men, with women potentially experiencing more musculoskel-
etal related symptoms [3]. Sarcoidosis incidence also increases with family history 
of the disease; studies have shown that alleles on short arm of chromosome 6 seem 
to confer increased risk (HLA DR 11, 12, 14, 15, 17) or protection (HLA DRI, DR4) 
from disease [5].
Löfgren’s syndrome follows many of the same epidemiologic trends of sarcoidosis. 
It affects women more than men, with Scandinavian ethnicity having the highest 
incidence [6, 7]. There also seems to be a temporal clustering of incidence, with rates 
highest in the months from March to July [6]. The age of onset was, however; signifi-
cantly lower for Löfgren’s syndrome than sarcodosis, at 39 years old versus 47 years 
old [7]. There also are differences between sexes in regards to presentation, women are 
more likely to present with erythema nodosum, whereas men are more likely to have 
inflammation or arthritis of ankles without erythema nodosum [8]. Various genetic 
factors and alleles have been associated with Löfgren’s syndrome, some protective and 
leading to better outcomes (HLA DQB1*0201, DRB1*03) while others are associated 
with more severe disease and worse outcomes (CCR2, HLA DQ2, DR3) [6, 9–12].
3. Etiology
The etiology of sarcoidosis, and by extension Löfgren’s syndrome, is poorly 
understood. Granulomatous inflammation leads to eventual noncaseating granulo-
mas in various organs. Formation of granulomas is due to exaggerated cell mediated 
immune response to antigens. The exact antigen(s) that stimulate sarcoidosis is 
unclear at this point in time. Many studies analyzing a large number of patients 
have not found one factor(s) that clearly causes sarcoidosis [13], possibly due to 
there being many different underlying causes of sacroidosis that leads to similar 
presentations. Some of the possible etiologies explored to date are environmental 
exposures and infectious agents.
3.1 Environmental exposure
Certain chemical elements (Beryllium, Zirconium, Aluminum) have been 
shown to cause graulomatous disease in lungs of patients with occupational expo-
sure to these elements, while they themselves do not cause sarcoidosis, various stud-
ies have investigated if other environmental exposures could [14–16]. Specifically, 
rescue workers exposed to World Trade Center dust and debris developed new onset 
sarcoidosis, possible due to exposure to a yet unknown component of the dust [17].
3.2 Infectious agent
Mycobacterium and Propionibacteria have been studied as possible causes of 
sarcoidosis [18, 19]. Mycobacterium tuberculosis causes granulmatous caseations 
similar to those seen in sarcoidosis, and there have been Mycobacterium tuberculosis 
components found in sacroidosis tissue [20]. Propionibacteria acnes have also been 
found in lymph nodes of sarcoidosis patients [19]. Despite these findings, there has 
been no casual relationship found between these infectious agents and sacroidosis. 
Further evidence to support an infectious etiology of sarcoidosis is that transplanta-





The pathophysiology of sarcoidosis, and by extension Löfgren’s syndrome, 
involves activation of immune cells by as of yet unknown antigen(s). While the end 
result is graumloma formation, there are quite a few steps before this stage.
Antigen presenting cells (APCs), either macrophages or dendritic cells, 
phagocytose the as of yet unknown antigen(s), and then presents this antigen(s) 
to Helper CD4+ T cells. These Helper T cells then expresses various inflamma-
tory cytokines including: interferon-gamma, Tumor necrosis factor (TNF), 
interleukin (IL)-2, IL-17 and IL-22 [24]. IL-17 recruits T Helper 17 (Th17) cells 
which then produce even more inflammatory cytokines, primarily interferon-
gamma [25]. All these inflammatory mediators cause fusion of APCs into 
multinucleated giant cells, the APCs and multinucleated giant cells then cluster 
to form granulomas.
This process seems to occur most prominent and commonly in the lungs, with 
alveolar macrophages often the first to aggregate to form granulomas. This process 
can occur in other areas of the body, as evidence by up to 30% of patient experienc-
ing extrapulmonary symptoms (Figure 1) [26].
4.1 Erythema Nodosum and acute polyarthritis
In Löfgren’s syndrome, in addition to pulmonary granolumas (represented as 
hilar adenopathy), there are also manifestations of erythema nodosum and acute 
polyarthritis. Erythema nodosum is caused by delayed type hypersensitivity  
reaction from exposure to antigens. Its exact pathophysiology is not fully under-
stood, but may be due to immune complex deposition in venules of subcutaneous 
Figure 1. 
Non-caseating granuloma (Samir at the English-language Wikipedia, CC BY-SA 3.0 <http://creativecommons.
org/licenses/by-sa/3.0/>, via Wikimedia Commons).
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fat, inciting an inflammatory reaction and granuloma formation [27]. Acute 
polyarthritis also has poorly understood pathogenesis, but may be due increased 
inflammatory milieu within the body, leading to transient inflammatory arthritis.
5. Presentation
Löfgren’s syndrome presents classically as a triad of hilar lympadenopathy, 
erythema nodosum and acute polyarthritis. Often constitutional symptoms occur 
concurrently with the above triad, most commonly manifesting as fever, fatigue 
and malaise. Age of onset is generally under or around 40 years of age. More rare 
symptoms include uveitis along with blurry vision and light sensitivity [28]. There 
is variability in presentation between different sexes [8].
5.1 Hilar lymphadenopathy
Hilar lyphadenopathy is a classic finding of pulmonary sarcoidosis, making it 
ubiquitous in Löfgren’s syndrome. It is a radiographic term for enlarged mediastinal 
lymph nodes, most often those surrounding the pulmonary hila or root of the 
lung, where the lungs connect to the trachea and heart. Often the enlargement is 
bilateral and symmetric, though the right side may be slightly more prominent. 
Chest radiograph is required for definitive diagnosis, and there are five stages, as 
discussed below. These stages do not represent disease activity, just anatomical 
findings on chest radiography [29]. Generally, hilar lympadenopathy will regress 
within 1 year [30]. Though not exclusively caused by bilateral hilar lympadenopa-
thy, respiratory symptoms are often the first presentation that prompts obtaining 
a chest radiograph, where hilar lymphadenopathy is first discovered in a patient. 
These respiratory symptoms most commonly are coughing, dyspnea and chest pain 
(Table 1 and Figures 2 and 3).
5.2 Erythema Nodosum
Erythema nodosum presents as erythematous, tender, immobile nodules that 
are elevated and can join to form a plaque. Most commonly, they present on shins 
in Löfgren’s syndrome, though they can also appear on head and neck regions as 
well. These nodules are caused by subcutaneous inflammation, and are frequently 
accompanied by fevers and take a few days to develop. Spontaneous resolution 
typically occurs within eight weeks without scarring. There may be hyperpig-
mentation after resolution, but this is rare [27]. Relapsing erythema nodosum 
Stages of Pulmonary 
Sarcoidosis
Features
Stage 0 Normal chest radiograph
Stage I Bilateral hilar lymphadenopathy
Stage II Bilateral hilar lymphadenopathy + Diffuse infiltrative lung damage
Stage III Diffuse infiltrative lung damage
Stage IV Lung fibrosis1
1The Foundations in Diagnostic Pathology Series, Pulmonary Pathology – Chapter 17.
Table 1. 




can develop; this represents poor control or failure of treatment of underlying 
chronic condition. Erythema nodosum is also more commonly seen in women with 
Löfgren’s syndrome, whereas men can have acute polyarthritis with no erythema 
nodosum (Figure 4) [8].
5.3 Acute polyarthritis
Acute polyarthritis in Löfgren’s syndrome is typically symmetrical and oligoar-
ticular (affecting 2 to 4 joints) initially. Most often, it involves the ankles bilaterally 
and then starts to affects other joints of the lower extremities such as knees and 
Figure 2. 
Anterior–posterior and lateral chest radiograph of bilateral hilar lymphadenopathy (image courtesy of H. 
Bruce Dull, MD).
Figure 3. 




can also affect wrists and elbow joints as well. Bilateral ankle arthritis seems to be 
the most common initial manifestation of acute polyarthritis. Rarely, small joints 
of hands bilaterally can be involved [30]. Arthritis generally resolves within a few 
months, though it can persist up to 2 years, even with treatment. Cases of recur-
rent arthritis after treatment have also been described [31]. Men present with acute 
polyarthritis more commonly [8].
6. Evaluation and diagnosis
There are no definitive test or classification criteria for Löfgren’s syndrome, and 
though the classic triad of hilar lympadenopathy, erythema nodosum and acute poly-
arthritis are highly specific (> 95%), there are instances where not all components 
are presents in patients with Löfgren’s syndrome [32]. For successful evaluation of 
a patient with Löfgren’s syndrome, an accurate and detail history and physical must 
first be performed, usually followed up with a chest radiograph to confirm diagnosis. 
Biopsies may be indicated for definitive diagnosis of sarcoidosis if chest radiograph 
or other forms of imaging are inconclusive. Laboratory testing is generally not 
required.
6.1 History and physical exam
A detailed and accurate history and physical exam is essential for evaluation and 
diagnosis of Löfgren’s syndrome. Chronicity and specificity symptoms need to be 
elucidated and investigated. Importantly, history should uncover onset and loca-
tion of acute polyarthritis, and whether there has been any migration of arthritis. 
Underlying arthritis or arthralgias should also be clarified, to ensure that the acute 
polyarthritis is indeed new and acute in nature, not a continuation of previous 
disease. Constitutional symptoms should also be inquired about, as acute onset 
of fever very often accompanies both the acute polyarthritis and development of 
erythema nodosum. Ask about respiratory symptoms, as they can be the first sign 
Figure 4. 





of previously unknown hilar lymphadenopathy. Keep in mind the differences in 
presentation between men and women, as women may not have presentation of 
acute polyarthritis and just erythema nodosum, whereas men may not present with 
erythema nodosum.
Physical exam should include detailed examination of lower extremities, neck and 
head regions for erythema nodosum. Joint examination of lower extremities as well 
as hands, wrists and elbows should be performed to see if there is pain, tenderness, 
swelling, redness and heat. Monitoring temperature can also be useful in determining 
if there is accompanying fever with these symptoms. A detailed cardiac, pulmonary 
and abdominal exam should be performed as hilar adenopathy and sarcoidosis in 
general can cause various manifestations and physical changes in these areas.
6.2 Chest radiography
Chest radiography should be obtained at least once on all patients suspected 
with Löfgren’s syndrome, it is an essential step to establishing if there his hilar 
lymphadenopathy. Section 5.1 describes findings and diagnostic criteria for hilar 
lymphadenopathy on chest radiograph. If chest radiography is inconclusive, high 
resolution computed tomography (HRCT) scan can be performed, and provides 
more detailed imaging and analysis of mesiatinum, able to identify in more detail 
the precise location and extent of lympadenopathy [33]. HRCT is not routinely 
recommended for evaluation and diagnosis of Löfgren’s syndrome.
6.3 Biopsies
Biopsies are generally limited to cases of Löfgren’s syndrome where HRCT or 
other imaging modalities cannot detect sarcoidosis, and/or disease is refractory to 
treatment or deviates from expected course. It is utilized to definitively obtain tissue 
samples that confirm diagnosis of sarcoidosis. Generally, bronchoalveolar lavage 
(BAL) is performed with endobronchial or transbronchial biopsies, endobronchial 
ultrasound (EBUS) biopsy can also be used for various positions and angles to 
attempt a needle aspiration biopsy of lympadenopathy. A triad of CD4 to CD8 cell 
ratio > 4, lymphocyte percentage > 16% and presence of noncaseating granulomas 
has 100% positive predictive value and 81% negative predictive value for diagnosis of 
sarcoidosis [34].
6.4 Laboratory and genetic testing
Laboratory testing is generally not required for evaluation and diagnosis of 
Löfgren’s syndrome. Many laboratory testing is non-specific and do not provide 
additional value. Exceptions may include angiotensin-converting enzyme (ACE) 
and ionized calcium. Studies have shown that patients with elevated ACE and 
ionized calcium may have increased risk for prolonged arthritis [35]. Tuberculosis 
skin or interferon-gamma testing should be performed at least once on patients 
suspected with Löfgren’s syndrome to rule out tuberculosis, which can mimic 
erythema nodosum as well as hilar adenopathy.
Genetic testing is not required for evaluation and diagnosis of Löfgren’s syn-
drome. Though some alleles and genes have been associated with Löfgren’s syn-
drome, they are more for academic research purposes rather than to diagnose the 
disease. Associations include: HLA DQB1*0201 and DRB1*03 have been found to be 
protective and lead to better outcomes, and CCR2, HLA DQ2 and DR3 have been 




Many conditions and diseases can cause erythema nodosum, polyarthritis 
and associated fever. These including: infections, drug reactions, malignancies, 
inflammatory bowel disease and other rheumatologic conditions. While chest 
radiograph with findings of hilar adenopathy can significantly increase specific-
ity for Löfgren’s syndrome, it is not always necessary and a detailed history and 
physical should be able to differentiate many of the other differential diagnoses 
listed below.
7.1 Infections
A wide variety of infections can cause erythema nodosum and arthritis, which 
can manifest as reactive arthritis or infectious arthritis. These include bacterial: 
streptococcous, chalymdia, yersinina, salmonella, campylobacter and tubcerculo-
sis. Fungal: coccidiomycosis, histoplasmosis, blastomycosis. Viral: hepatitis B and 
infectious mononucleosis. Reactive and infectious arthritis generally present ini-
tially in the knee joint, which can overlap with Löfgren’s syndrome, and the arthritis 
are also usually self-limited and acute. Therefore it can be difficult to distinguish 
between the two without chest radiography, but presence of hilar lymphadenopathy 
should exclude most of the infections listed above. The exception to this is tuber-
culosis, which can also present with hilar adenopathy, thus it is necessary to obtain 
tuberculosis skin or interferon-gamma testing to rule out tuberculosis infection.
7.2 Drug reactions
Drug reactions that can cause erythema nodosum include: oral contraceptives, 
penicillins, sulfonamides, bromides, iodides and TNF Alpha inhibitors. Though 
drug reactions can cause fever, very rarely do they cause arthritis. Cessation of 
offending drug also often resolves symptoms. Thus, if there is no presence of acute 
polyarthritis, distinguishing a drug reaction from Löfgren’s syndrome is clear.
7.3 Malignancies
Malignancies that can cause erythema nodosum include lymphoma, leukemia 
and carcinomas. These malignancies can also be associated with fever, but also very 
rarely cause arthritis. They can, however, cause hilar lymphadenopathy, thus it is 
important to delineate presence of acute polyarthritis.
7.4 Inflammatory bowel disease (IBD)
Ulcerative colitis and Crohns disease can cause erythema nodosum with 
associated fever as well as enteropathic arthritis. Enteropathic arthritis can pres-
ent sporadically and intermittently, and can be mistaken for acute polyarthritis. 
Therefore, it is difficult to distinguish between inflammatory bowel disease and 
Löfgren’s syndrome, chest radiography should be obtained to detect for presence of 
hilar adenopathy. IBD generally does not cause hilar lymphadenopathy.
7.5 Other rheumatologic conditions
Rheumatologic conditions such as Behcet disease and Sweet syndrome can also 
cause erythema nodosum, arthritis with associated fevers. Behcet syndrome causes 




syndrome itself does not cause arthritis, but is associated with rheumatoid arthritis, 
IBD and Behcet syndrome, all of which can cause arthritis. Sweet syndrome is asso-
ciated with a characteristic rash that present as erythematous plaques, which should 
be differentiated from erythema nodosum. Neither condition is associated with 
hilar lymphadenopathy, thus chest radiography should be obtained to distinguish 
them from Löfgren’s syndrome.
8. Treatment/management
Löfgren’s syndrome is largely a self-limited disease, the erythema nodosum, 
acute polyarthritis and hilar lymphadenopathy resolves usually within a few weeks 
to months, most cases resolve within 1 year. Polyarthritis has been known to last up 
to 2 years. Treatment is largely supportive and goal is symptomatic control. NSAIDs 
are first line for anti-inflammatory properties to ameliorate discomfort of fever, 
erythema nodosum and arthritis; colchcine can also be used for this purpose. In 
severe or refractory cases, glucocorticoids can be used, which needs to be tapered 
off of once symptoms have been resolved. Further interventions with methotrexate 
or hydroxychloroquine can also be used, and infiximab beyond that [36].
9. Prognosis
Prognosis of Löfgren’s syndrome is excellent; most patients achieve complete 
resolution of symptoms without recurrence in 6 months to 2 years. Cases have been 
described of recurrence of symptoms or progression to chronic disease, but these 
are exceedingly rare [35].
10. Conclusions
Löfgren’s syndrome is a rare disease that is often misdiagnosed or under diag-
nosed. The constellation of symptoms of erythema nodosum, acute polyarthritis 
(most commonly bilaterally in ankle and under 2 months since time of onset) as 
well as hilar lymphadenopathy in a young patient (under 40 years of age) should 
raise very high suspicions for this disease. Prompt recognition and treatment of this 
disease can save much stress and pain for patients afflicted by it.
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